Jill S. Clancy
Pfizer (United States)(US)
Publications by Year
Research Areas
Lung Cancer Treatments and Mutations, Lung Cancer Research Studies, Lung Cancer Diagnosis and Treatment, Cancer Genomics and Diagnostics, Colorectal Cancer Treatments and Studies
Most-Cited Works
- → Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study(2018)776 cited
- → Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial(2017)645 cited
- → Phase III Study to Evaluate Temsirolimus Compared With Investigator's Choice Therapy for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma(2009)639 cited
- → ALK Resistance Mutations and Efficacy of Lorlatinib in Advanced Anaplastic Lymphoma Kinase-Positive Non–Small-Cell Lung Cancer(2019)375 cited
- → Lorlatinib in advanced ROS1-positive non-small-cell lung cancer: a multicentre, open-label, single-arm, phase 1–2 trial(2019)350 cited
- → Randomized Phase III Trial of Temsirolimus and Bevacizumab Versus Interferon Alfa and Bevacizumab in Metastatic Renal Cell Carcinoma: INTORACT Trial(2013)210 cited
- → Phase II trial of temsirolimus in children with high-grade glioma, neuroblastoma and rhabdomyosarcoma(2011)141 cited
- → Phase I Study of Temsirolimus in Pediatric Patients With Recurrent/Refractory Solid Tumors(2011)94 cited
- → Safety and efficacy of lorlatinib (PF-06463922) from the dose-escalation component of a study in patients with advanced ALK+ or ROS1+ non-small cell lung cancer (NSCLC).(2016)90 cited
- → Clinical activity and safety of PF-06463922 from a dose escalation study in patients with advanced ALK+ or ROS1+ NSCLC.(2015)42 cited